DNA修复基因XPC多态性与头颈部肿瘤易感性关系的meta分析  

Meta Analysis on DNA Repair Gene XPC A939C Single Neucleotide Polymorphisms and Head and Neck Cancer Susceptibility

作　　者：李杰[1] 柯为洵[1] 曹岐新[1] 

机构地区：[1]浙江中医药大学附属湖州中医院耳鼻咽喉科,313000

出　　处：《医学研究杂志》2012年第1期115-117,共3页Journal of Medical Research

摘　　要：目的 DNA修复基因XPC多态性与头颈部肿瘤易感性关系已有广泛研究,但研究结果不完全一致。本研究采用系统评价的方法探讨DNA修复基因XPC多态性与头颈部肿瘤易感性的关系。方法检索PubMed、EMBASE、中国生物医学文献数据库CBM、中国期刊全文数据库CNKI等公开发表的关于DNA修复基因A939C单核苷酸多态性与头颈部肿瘤易感性的病例-对照研究进行Meta分析。病例组及对照组XPC A939C等位基因分布的比数比(odds ratio,OR)为效应指标,应用统计软件STATA11.0进行数据分析。结果纳入文献研究4篇,Meta分析结果显示:分别以野生型纯合子(A/A)和主要基因型为对照(A/A+A/C),XPC A939C位点突变纯合子(C/C)个体头颈部肿瘤发生风险的OR值分别为1.37和1.20(OR=1.37,95%CI:0.97～1.93,P=0.070;OR=1.20,95%CI:0.87～1.66,P=0.258)。结论 DNA修复基因XPC A939C单核苷酸多态性与头颈部肿瘤易感性间不存在明显相关性,但纳入研究的数量及每个研究的样本量均较少,需加大样本量进一步研究。The relationship between DNA repaire gene XPC A939C single neucleotide polymorphisms and head and neck cancer susceptibility has been studied extensively. However, the outcomes are not consistent. The aim of this study is to evaluate the relationship between DNA repaire gene XPC A939C single neucleotide polymorphisms and head and neck cancer susceptibility by meta a- nalysis. Methods By searching Medline, EMBSE, CBM and CNKI et al, we collected all case -control and cohort studies about DNA repaire gene XPC A939C single neucleotide polymorphisms and head and neck cancer susceptibility. The odds ratios（OR） of variant allele of XPC A939C was calculated by using statistic software STATA11.0. Results Four case - control studies were identified for the meta a- nalysis. The OR was 1.37 and 1.20 for the C/C group compared to the A/A group（ OR = 1.37,95% CI：0.97 -1.93,P =0. 070） and AA ＋ AC group （ OR = 1.20,95% CI：0.87 - 1.66, P = 0. 258 ） respectively. Conclusion There was no relationship between DNA re- paire gene XPC A939C single neucleotide polymorphisms and head and neck cancer susceptibility. But for the small number trials and subjects included in this paper, further studies is needed for the meta analysis.

关 键 词：头颈部肿瘤DNA修复基因 单核苷酸多态性meta分析 

分 类 号：R734.2[医药卫生—肿瘤]